DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the ACUTAAS CHEMICALS LIMITED (ACUTAAS) share price today?

ACUTAAS CHEMICALS LIMITED (ACUTAAS) is trading at ₹3,619.4 on the NSE, up 0.99% on the day. Source: DocStoX.

What is the PE ratio of ACUTAAS CHEMICALS LIMITED?

ACUTAAS CHEMICALS LIMITED has a price-to-earnings (PE) ratio of 83.2 in the Healthcare sector.

What is the market capitalisation of ACUTAAS CHEMICALS LIMITED?

ACUTAAS CHEMICALS LIMITED has a market capitalisation of approximately ₹29,728 crore.

ACUTAAS CHEMICALS LIMITED

ACUTAAS·NSE·Healthcare

₹3,619.40▲ +35.60 (+0.99%)

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

NIFTY 500NIFTY SMALLCAP 250

Day₹3545.00

₹3634.00

52W₹1124

₹374095%

Open

₹3591.00

High

₹3634.00

Low

₹3545.00

Prev Close

₹3583.80

Volume

1.88L

VWAP

₹3586.42

Snapshot

Key fundamentals

Market Cap

₹29,728 Cr

P/E Ratio

83.19Expensive

P/B Ratio

17.13

EPS

₹43.51

Book Value

₹202.00

ROE

24.00%Strong

ROCE

32.00%Efficient

Dividend Yield

0.04%

Debt / Equity

0.02Low

Face Value

₹5.00

52W High

₹3740.00

52W Low

₹1123.86

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹367

▼ 89.9%downside

Trading at ₹3,619 — 90% above our estimate

BearFair valueBull

₹312₹367₹445

/100

Business quality — Solid

Growth 100Profitability 98Efficiency 50Valuation 50

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet
Expensive — trades at 83× earnings

Strengths

Virtually debt-free balance sheet
Strong returns on equity (24%)
Capital is working hard (ROCE 32%)
Revenue compounding 29% over 3 years

Risks

Expensive — trades at 83× earnings
Fundamental red flags (Piotroski 3/9)

How we got there

Fair value methods

Residual income

24% ROE fading to 12% over ~10 yrs, on ₹202 book

₹345

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹445

Analyst target

No analyst coverage

—

Blended fair value₹367

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Strong returns on equity (24%)
Capital is working hard (ROCE 32%)
Revenue compounding 29% over 3 years
Profit growing 62% a year

Bear case

Expensive — trades at 83× earnings
Fundamental red flags (Piotroski 3/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

83.2Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

24.0%Strong

Above 15% is considered healthy for Indian equities

ROCE

32.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.02Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹29,728 Cr

P/B

17.13

EPS

₹43.51

Div Yield

0.04%

What changed

Recent changes

Foreign investors+2.1% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 83.2×

Growth

Strong

+29% rev CAGR

Profitability

Excellent

24.0% ROE

Financial health

Rock solid

D/E 0.02

Momentum

N/A

No technicals

Today

Trading activity

Delivery %51.4%

Turnover₹6739.28L Cr

Trades16,769

VWAP₹3586.42

Face value₹5.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+29.5%

+31.5%

10Y

—

Profit

+62.5%

+45.8%

10Y

—

EPS

+56.1%

+38.4%

10Y

—

Profile

Pros

Company is almost debt free.
Company is expected to give good quarter
Company has delivered good profit growth of 45.8% CAGR over last 5 years

Watch-outs

Cons

Stock is trading at 16.8 times its book value
Promoter holding has decreased over last 3 years: -6.75%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Foreign investors bought 2.13 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

33%

Promoter

Promoters

32.7%0.00

Public

26.2%-2.08

FII / FPI

21.6%+2.13

DII

19.6%-0.05

Quarterly trend

Ownership over time

Q1 FY27

Promoter32.66%

FII21.61%

DII19.55%

Public26.16%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions